TY - JOUR

T1 - Chronic heart failure and diabetes mellitus

T2 - Pathogenesis and possibilities of treatment

AU - Obrezan, A. G.

AU - Kulikov, N. V.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In this article we present data of scientific studies of prevalence of diabetes mellitus (DM) among patients with chronic heart failure (CHF), pathogenetic and risk factors of CHF development patients with DM (hyperglycemia, elevated body mass index, age, ischemic heart disease, nephropathy, proteinuria, DM duration, etc.). The article also contains results of analysis of mortality of patients with and without DM in dependence of ejection fraction value. After characterization of drugs for treatment of CHF in general and specifically in patients with DM we make focus on perspective directions in treatment of this group of patients. Sodium-glucose co-transporter 2 (SGLT2) inhibitors can be effective in patients with DM and CHF, in the first place empagliflozin with proven positive cardiac effects. In obese patients with and without DM efficacy of treatment at the background of lifestyle modification with the help of weight reduction, physical exercise, diet etc has been shown to be effective. In addition, there are data on positive effects of metformin which in patients with CHF and DM lowers availability of energy substrate at the account of reduction of volume of endogenous glucose.

AB - In this article we present data of scientific studies of prevalence of diabetes mellitus (DM) among patients with chronic heart failure (CHF), pathogenetic and risk factors of CHF development patients with DM (hyperglycemia, elevated body mass index, age, ischemic heart disease, nephropathy, proteinuria, DM duration, etc.). The article also contains results of analysis of mortality of patients with and without DM in dependence of ejection fraction value. After characterization of drugs for treatment of CHF in general and specifically in patients with DM we make focus on perspective directions in treatment of this group of patients. Sodium-glucose co-transporter 2 (SGLT2) inhibitors can be effective in patients with DM and CHF, in the first place empagliflozin with proven positive cardiac effects. In obese patients with and without DM efficacy of treatment at the background of lifestyle modification with the help of weight reduction, physical exercise, diet etc has been shown to be effective. In addition, there are data on positive effects of metformin which in patients with CHF and DM lowers availability of energy substrate at the account of reduction of volume of endogenous glucose.

KW - Diabetes mellitus

KW - Heart failure

KW - Pathogenesis

KW - Treatment.

UR - http://www.scopus.com/inward/record.url?scp=85057557499&partnerID=8YFLogxK

U2 - 10.18087/cardio.2018.7.10156

DO - 10.18087/cardio.2018.7.10156

M3 - Article

C2 - 30081813

AN - SCOPUS:85057557499

VL - 58

SP - 85

EP - 94

JO - КАРДИОЛОГИЯ

JF - КАРДИОЛОГИЯ

SN - 0022-9040

IS - 7

ER -